Article

Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.

Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Italy.
Pharmacoepidemiology and Drug Safety (Impact Factor: 2.9). 07/2012; DOI: 10.1002/pds.3328
Source: PubMed

ABSTRACT PURPOSE: Review all the individualized cases of adverse drug reaction (ADR) potentially related to buflomedil, a vasodilator with the indication for peripheral arterial disease (PAD), marketed in Europe since the 1970s but recently suspended by the European Medicines Agency. METHODS: A review of all available individualised case safety data relating to oral buflomedil from the buflomedil global safety database (provided by the manufacturer of buflomedil), the worldwide published medical literature, toxicology/poison centres and regulatory authorities. RESULTS: The main ADRs reported were in the cardiovascular (CVS) and nervous systems (NS), grouped under four (MedDRA) System Organ Classes (SOCs): (i) Cardiac disorders; (ii) Vascular disorders; (iii) Investigations; (iv) NS disorders. From an initial cumulative number of 1054 case reports, there were 401 cases of intentional overdose (IOD) of which 63 were fatal, and 137 cases of accidental overdose, with two fatalities, and 516 case reports of ADRs under normal conditions of use of the product at normal therapeutic dosage with 11 fatalities. Overdosage (intentional or accidental) represented 50.9% of cases, with 47.6% of patients <40 years of age. The indications for which these young patients were prescribed buflomedil were not reported in most cases. CONCLUSIONS: The main indication of buflomedil is PAD; however, because most cases of IOD occurred in people <40 years of age, where PAD is unlikely, it is possible that buflomedil was prescribed for other indications and/or that it was not directly prescribed to the end user, who rather gained access to the medication prescribed to family members or friends. Copyright © 2012 John Wiley & Sons, Ltd.

0 Bookmarks
 · 
88 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Earlier investigations have demonstrated that buflomedil, a substance which is successful in the clinical treatment of peripheral vascular disease, exerts an inhibitory effect on ADP-induced aggregation ex vivo and in vitro. In the presented study the effect of buflomedil on platelets is investigated. Clinically widely used platelet function tests were performed after a single oral dose of buflomedil (300 mg) to healthy volunteers. Again, an ex vivo inhibition of ADP-induced aggregation was confirmed. None of the other parameters examined was influenced by the administered drug, such as plasma thromboxane B2, the platelet proteins, the platelet sensitivity to antiaggregatory prostaglandins and the prostacyclin synthesis stimulating plasma factor.
    Wiener klinische Wochenschrift 10/1985; 97(18):720-2. · 0.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An examination was made of the behaviour of platelet function after a single i.v. injection of 150 mg Buflomedil in 8 non-diabetic vasculopathic patients. The drug was followed by a significant reduction of the platelet aggregability induced by ADP and adrenaline, but not by collagen, and did not alter the percentage of reversible circulating platelet aggregates. Its action was limited in time, since no activity was observed after 24 hr. The drug was also clinically evaluated in 30 patients aged over 80 yr with chronic cerebrovascular insufficiency, following treatment with 100 mg/day i.v. for 20 days, and then 450 mg/day per os for 80 days. Significant improvements were noted in vertigo, tinnitus, lapses of memory, and the ability to remember numbers. The results were less impressive with regard to insomnia, migraine, and asthenia.
    Minerva medica 08/1983; 74(28-29):1727-31. · 0.77 Impact Factor
  • Journal de toxicologie clinique et expérimentale 01/1988; 8(4):243-6.

Full-text

View
37 Downloads
Available from
Jun 4, 2014